Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025:2940:165-171.
doi: 10.1007/978-1-0716-4615-1_15.

Engineering of Vesicular Stomatitis Virus (VSV) for Modulating Cell Death and Antitumor Immunity

Affiliations

Engineering of Vesicular Stomatitis Virus (VSV) for Modulating Cell Death and Antitumor Immunity

Tao Yang et al. Methods Mol Biol. 2025.

Abstract

Vesicular stomatitis virus (VSV), a negative-sense RNA virus, has emerged as a versatile platform for oncolytic virotherapy and vaccine development. Numerous advantages, such as a broad host range, rapid replication, and simple and easily modifiable genomes, make it an attractive candidate for both the treatment and prevention of infectious diseases and tumors. Advances in molecular biology techniques, particularly reverse genetics and synthetic biology, have facilitated the precise engineering of VSV genomes, thereby significantly expanding their applications in cancer therapeutics. One of the most common antitumor strategies is to promote tumor cell death. Numerous studies have shown that engineered VSV with cell death elements has considerable antitumor efficacy. This chapter provides a comprehensive overview of VSV engineering techniques, focusing specifically on the incorporation of the proapoptotic gene XAF1, along with detailed experimental procedures. The goal of these approaches is to increase the efficacy of VSV in antitumor immunity and other therapeutic domains.

Keywords: Antitumor immunity; Cell death; Reverse genetic system; VSV.

PubMed Disclaimer

Similar articles

References

    1. Lawson ND, Stillman EA, Whitt MA et al (1995) Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci USA 92(10):4477–4481 - DOI - PubMed - PMC
    1. Banerjee AK (1987) The transcription complex of vesicular stomatitis virus. Cell 48(3):363–364 - DOI - PubMed
    1. Johannsdottir HK, Mancini R, Kartenbeck J et al (2009) Host cell factors and functions involved in vesicular stomatitis virus entry. J Virol 83(1):440–453 - DOI - PubMed
    1. Bishnoi S, Tiwari R, Gupta S et al (2018) Oncotargeting by vesicular stomatitis virus (VSV): advances in cancer therapy. Viruses 10(2)
    1. Naik S, Nace R, Federspiel MJ et al (2012) Curative one-shot systemic virotherapy in murine myeloma. Leukemia 26(8):1870–1878 - DOI - PubMed - PMC

LinkOut - more resources